Hepatitis B Virus S Protein, Pre-S1 Protein And Pre-S2 Protein Virus Like Particles

CHEMBL6068346 Phase 4 Approuvé Vaccine component
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This vaccine component contains virus-like particles that mimic the hepatitis B virus surface, training your immune system to recognize and fight the virus. It is used as part of hepatitis B vaccination to provide long-lasting protection against infection and its serious complications, including liver damage and cancer.

Mécanisme d'action

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This vaccine component contains virus-like particles that mimic the hepatitis B virus surface, training your immune system to recognize and fight the virus. It is used as part of hepatitis B vaccination to provide long-lasting protection against infection and its serious complications, including liver damage and cancer.

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Yes, Hepatitis B Virus S Protein, Pre-S1 Protein And Pre-S2 Protein Virus Like Particles is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068346. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.